SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : analysts and calls -- B of A -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (24)1/15/2005 3:26:12 PM
From: Biomaven  Read Replies (1) | Respond to of 33
 
I agee - this is silly in just so many ways. Looking at CAGR in the first place is generally dumb for most early-stage biotechs, and then they discount back by 53%. Why 53%? Using a number like that makes it look like there is some precision behind their methodology.

Peter



To: scaram(o)uche who wrote (24)1/15/2005 8:06:35 PM
From: tom pope  Respond to of 33
 
I assume they mean the CAGR of revenues. Given that a small biotech's revenues are lumpy or virtually non existent, how did this pass any sort of laugh test?

CAGR of R&D expense might be more a bit more meaningful. A bit.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News